CDKN2B and hepatocellular carcinoma: Among 15 sarcomatoid HCC patients, 7 (46.6%) had genetic variants in cell cycle pathway genes (4 CDKN2A, 1 CDKN2B, and 2 CCND1), which was significantly higher than that (14.7%, 11/75) in non‐sarcomatoid HCC patients (p = 0.013).